Sutro Biopharma (STRO) IPO Opens Modestly Higher

Go back to Sutro Biopharma (STRO) IPO Opens Modestly Higher

Sutro Biopharma Announces $85.0 Million Initial Public Offering

September 26, 2018 6:58 PM UTC

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Sutro. The shares are expected to begin trading on The Nasdaq Global Market on September 27, 2018 under the symbol... More